EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, AVEO Pharmaceuticals's enterprise value is $482.73 Mil.
AVEO Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 was $-24.37 Mil. Therefore, AVEO Pharmaceuticals's EV-to-EBITDA for today is -19.81.
The historical rank and industry rank for AVEO Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
AVEO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -132.41 Med: -2.76 Max: 66
Current: -19.81
During the past 13 years, the highest EV-to-EBITDA of AVEO Pharmaceuticals was 66.00. The lowest was -132.41. And the median was -2.76.
AVEO's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.535
vs AVEO: -19.81
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
AVEO Pharmaceuticals EV-to-EBITDA Historical Data
The historical data trend for AVEO Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AVEO Pharmaceuticals's EV-to-EBITDA
For the Biotechnology subindustry, AVEO Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AVEO Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AVEO Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where AVEO Pharmaceuticals's EV-to-EBITDA falls into.
AVEO Pharmaceuticals's current Enterprise Value is $482.73 Mil.
AVEO Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.37 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
AVEO Pharmaceuticals's PE Ratio for today is calculated as:
AVEO Pharmaceuticals's share price for today is $15.00.
AVEO Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.840.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of AVEO Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
AVEO Pharmaceuticals (AVEO Pharmaceuticals) Business Description
AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AVEO has been successfully added to your 